# GENELUX Corp: financial statements, quarterly

GNLX · Nasdaq · CIK 1231457 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gnlx.md) · [Financials](/companies/gnlx/financials.md) · [Filings](/companies/gnlx/filings.md) · [Insiders](/companies/gnlx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gnlx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0 d](/filings/0001493152-24-045790.md) | [0.0 d](/filings/0001641172-25-001184.md) | [8.0](/filings/0001641172-25-008838.md) | [0.0 d](/filings/0001641172-25-022583.md) | [0.0 d](/filings/0001493152-25-020874.md) | [0.0 d](/filings/0001493152-26-011616.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [2,819](/filings/0001493152-24-045790.md) | [4,160 d](/filings/0001641172-25-001184.md) | [4,010](/filings/0001641172-25-008838.md) | [4,417](/filings/0001641172-25-022583.md) | [4,051](/filings/0001493152-25-020874.md) | [6,520 d](/filings/0001493152-26-011616.md) | [4,698](/filings/0001493152-26-021710.md) | [4,758](/filings/0001493152-26-037667.md) | [4,741](/filings/0001493152-25-020874.md) | [5,654 d](/filings/0001493152-26-011616.md) | [5,778](/filings/0001493152-26-021710.md) | [6,508](/filings/0001493152-26-037667.md) |
| Operating income | $k | [(5,307)](/filings/0001493152-24-045790.md) | [(7,001) d](/filings/0001641172-25-001184.md) | [(8,115)](/filings/0001641172-25-008838.md) | [(6,892)](/filings/0001641172-25-022583.md) | [(6,941)](/filings/0001493152-25-020874.md) | [(9,748) d](/filings/0001493152-26-011616.md) | [(7,816)](/filings/0001493152-26-021710.md) | [(7,792)](/filings/0001493152-26-037667.md) | [(8,194)](/filings/0001493152-25-020874.md) | [(9,412) d](/filings/0001493152-26-011616.md) | [(9,171)](/filings/0001493152-26-021710.md) | [(9,645)](/filings/0001493152-26-037667.md) |
| Interest expense | $k | not reported | [6.0 d](/filings/0001641172-25-001184.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(5,345)](/filings/0001493152-24-045790.md) | [(6,767) d](/filings/0001641172-25-001184.md) | [(7,850)](/filings/0001493152-25-020874.md) | [(6,576)](/filings/0001493152-25-020874.md) | [(6,467)](/filings/0001493152-25-020874.md) | [(8,976) d](/filings/0001493152-26-011616.md) | [(7,492)](/filings/0001493152-26-037667.md) | [(7,456)](/filings/0001493152-26-037667.md) | [(7,950)](/filings/0001493152-25-020874.md) | [(9,247) d](/filings/0001493152-26-011616.md) | [(8,928)](/filings/0001493152-26-037667.md) | [(9,471)](/filings/0001493152-26-037667.md) |
| Diluted EPS | $ per share | [(0.20)](/filings/0001493152-24-045790.md) | not reported | [(0.29)](/filings/0001641172-25-008838.md) | [(0.22)](/filings/0001641172-25-022583.md) | [(0.19)](/filings/0001493152-25-020874.md) | not reported | [(0.21)](/filings/0001493152-26-021710.md) | [(0.20)](/filings/0001493152-26-037667.md) | [(0.21)](/filings/0001493152-25-020874.md) | not reported | [(0.20)](/filings/0001493152-26-021710.md) | [(0.21)](/filings/0001493152-26-037667.md) |
| Basic EPS | $ per share | [(0.20)](/filings/0001493152-24-045790.md) | not reported | [(0.29)](/filings/0001641172-25-008838.md) | [(0.22)](/filings/0001641172-25-022583.md) | [(0.19)](/filings/0001493152-25-020874.md) | not reported | [(0.21)](/filings/0001493152-26-021710.md) | [(0.20)](/filings/0001493152-26-037667.md) | [(0.21)](/filings/0001493152-25-020874.md) | not reported | [(0.20)](/filings/0001493152-26-021710.md) | [(0.21)](/filings/0001493152-26-037667.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [29.9](/filings/0001493152-23-041151.md) | [9.4](/filings/0001641172-25-001184.md) | [4.1](/filings/0001493152-24-018436.md) | [7.9](/filings/0001493152-24-032145.md) | [6.1](/filings/0001493152-24-045790.md) | [8.6](/filings/0001493152-26-011616.md) | [16.2](/filings/0001641172-25-008838.md) | [6.5](/filings/0001641172-25-022583.md) | not reported | [5.3](/filings/0001493152-26-037667.md) | [9.3](/filings/0001493152-26-021710.md) | [9.2](/filings/0001493152-26-037667.md) |
| Current assets | $m | [31.2](/filings/0001493152-23-041151.md) | [24.2](/filings/0001641172-25-001184.md) | [21.2](/filings/0001493152-24-018436.md) | [34.9](/filings/0001493152-24-032145.md) | [36.0](/filings/0001493152-24-045790.md) | [31.5](/filings/0001493152-26-011616.md) | [35.9](/filings/0001641172-25-008838.md) | [29.2](/filings/0001641172-25-022583.md) | [21.6](/filings/0001493152-25-020874.md) | [15.1](/filings/0001493152-26-037667.md) | [26.8](/filings/0001493152-26-021710.md) | [19.1](/filings/0001493152-26-037667.md) |
| Total assets | $m | [34.1](/filings/0001493152-23-041151.md) | [27.9](/filings/0001641172-25-001184.md) | [24.7](/filings/0001493152-24-018436.md) | [45.2](/filings/0001493152-24-032145.md) | [40.3](/filings/0001493152-24-045790.md) | [34.7](/filings/0001493152-26-011616.md) | [39.0](/filings/0001641172-25-008838.md) | [32.2](/filings/0001641172-25-022583.md) | [25.0](/filings/0001493152-25-020874.md) | [19.0](/filings/0001493152-26-037667.md) | [32.4](/filings/0001493152-26-021710.md) | [26.2](/filings/0001493152-26-037667.md) |
| Current liabilities | $m | [8.8](/filings/0001493152-23-041151.md) | [6.6](/filings/0001641172-25-001184.md) | [7.8](/filings/0001493152-24-018436.md) | [5.8](/filings/0001493152-24-032145.md) | [5.6](/filings/0001493152-24-045790.md) | [6.9](/filings/0001493152-26-011616.md) | [7.7](/filings/0001641172-25-008838.md) | [7.0](/filings/0001641172-25-022583.md) | [5.1](/filings/0001493152-25-020874.md) | [6.2](/filings/0001493152-26-037667.md) | [7.3](/filings/0001493152-26-021710.md) | [8.0](/filings/0001493152-26-037667.md) |
| Total liabilities | $m | [10.0](/filings/0001493152-23-041151.md) | [8.4](/filings/0001641172-25-001184.md) | [9.6](/filings/0001493152-24-018436.md) | [7.5](/filings/0001493152-24-032145.md) | [7.2](/filings/0001493152-24-045790.md) | [8.4](/filings/0001493152-26-011616.md) | [9.1](/filings/0001641172-25-008838.md) | [8.3](/filings/0001641172-25-022583.md) | [6.4](/filings/0001493152-25-020874.md) | [7.5](/filings/0001493152-26-037667.md) | [9.5](/filings/0001493152-26-021710.md) | [10.1](/filings/0001493152-26-037667.md) |
| Short-term borrowings | $m | [0.9](/filings/0001493152-23-041151.md) | [0.9](/filings/0001641172-25-001184.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [24.0](/filings/0001493152-24-045790.md) | [19.5](/filings/0001493152-26-011616.md) | [15.1](/filings/0001493152-25-020874.md) | [37.7](/filings/0001493152-25-020874.md) | [33.1](/filings/0001493152-25-020874.md) | [26.3](/filings/0001493152-26-037667.md) | [29.8](/filings/0001493152-26-037667.md) | [23.9](/filings/0001493152-26-037667.md) | [18.6](/filings/0001493152-25-020874.md) | [11.5](/filings/0001493152-26-037667.md) | [22.9](/filings/0001493152-26-037667.md) | [16.1](/filings/0001493152-26-037667.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,357) d](/filings/0001493152-24-045790.md) | [(6,910) d](/filings/0001641172-25-001184.md) | [(4,354)](/filings/0001641172-25-008838.md) | [(6,824) d](/filings/0001641172-25-022583.md) | [(5,748) d](/filings/0001493152-25-020874.md) | [(4,302) d](/filings/0001493152-26-011616.md) | [(5,435)](/filings/0001493152-26-021710.md) | [(7,059) d](/filings/0001493152-26-037667.md) | [(6,575) d](/filings/0001493152-25-020874.md) | [(6,199) d](/filings/0001493152-26-011616.md) | [(6,059)](/filings/0001493152-26-021710.md) | [(6,444) d](/filings/0001493152-26-037667.md) |
| Capital expenditure | $k | [277 d](/filings/0001493152-24-045790.md) | [243 d](/filings/0001641172-25-001184.md) | [30.0](/filings/0001641172-25-008838.md) | [228 d](/filings/0001641172-25-022583.md) | [27.0 d](/filings/0001493152-25-020874.md) | [96.0 d](/filings/0001493152-26-011616.md) | [30.0](/filings/0001493152-26-021710.md) | [115 d](/filings/0001493152-26-037667.md) | [517 d](/filings/0001493152-25-020874.md) | [436 d](/filings/0001493152-26-011616.md) | [921](/filings/0001493152-26-021710.md) | [1,532 d](/filings/0001493152-26-037667.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [10.1](/filings/0001493152-23-041151.md) | [19.6](/filings/0001493152-24-018436.md) | [25.1](/filings/0001493152-24-032145.md) | [26.2](/filings/0001493152-24-045790.md) | [26.8](/filings/0001641172-25-008838.md) | [29.7](/filings/0001641172-25-022583.md) | [34.5](/filings/0001493152-25-020874.md) | [34.9](/filings/0001493152-26-021710.md) | [37.9](/filings/0001493152-26-037667.md) | [37.9](/filings/0001493152-25-020874.md) | [44.2](/filings/0001493152-26-021710.md) | [45.0](/filings/0001493152-26-037667.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 45,245,335 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037667.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.